Get the Stockscreener App
0.7717
4.02%
0.0298
After Hours:
.75
-0.0217
-2.81%
Alx Oncology Holdings Inc stock is traded at $0.7717, with a volume of 315.24K.
It is up +4.02% in the last 24 hours and down -35.15% over the past month.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
See More
Previous Close:
$0.7419
Open:
$0.7622
24h Volume:
315.24K
Relative Volume:
0.27
Market Cap:
$41.20M
Revenue:
-
Net Income/Loss:
$-151.16M
P/E Ratio:
-0.2598
EPS:
-2.97
Net Cash Flow:
$-130.08M
1W Performance:
-19.56%
1M Performance:
-35.15%
6M Performance:
-64.44%
1Y Performance:
-93.32%
1-Day Range:
$0.731
$0.773
1-Week Range:
$0.731
$0.99
52-Week Range:
$0.731
$17.82
Alx Oncology Holdings Inc Stock (ALXO) Company Profile
Name
Alx Oncology Holdings Inc
Sector
Industry
Phone
650-466-7125
Address
323 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Compare ALXO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALXO
Alx Oncology Holdings Inc
|
0.7717 | 41.20M | 0 | -151.16M | -130.08M | -2.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
512.52 | 131.61B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.36 | 73.51B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
619.97 | 37.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.44 | 32.81B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
266.26 | 28.62B | 3.81B | -644.79M | -669.77M | -6.24 |
Alx Oncology Holdings Inc Stock (ALXO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-06-25 | Upgrade | Jefferies | Hold → Buy |
| Dec-19-24 | Downgrade | Jefferies | Buy → Hold |
| Mar-08-24 | Downgrade | Stifel | Buy → Hold |
| Dec-08-23 | Upgrade | Jefferies | Hold → Buy |
| Dec-22-21 | Downgrade | Jefferies | Buy → Hold |
| Sep-30-21 | Initiated | Stifel | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Apr-06-21 | Initiated | UBS | Buy |
| Feb-10-21 | Initiated | H.C. Wainwright | Buy |
| Aug-11-20 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-11-20 | Initiated | Credit Suisse | Outperform |
| Aug-11-20 | Initiated | Jefferies | Buy |
| Aug-11-20 | Initiated | Piper Sandler | Overweight |
View All
Alx Oncology Holdings Inc Stock (ALXO) Latest News
Why ALX Oncology Holdings Inc. (ALXO) Soared on Thursday - MSN
ALXO stock touches 52-week low at $0.89 amid market challenges - Investing.com Australia
ALXO stock touches 52-week low at $0.89 amid market challenges By Investing.com - Investing.com South Africa
Insider Buying: Rekha Hemrajani Acquires 30,000 Shares of ALX On - GuruFocus.com
ALX Oncology Holdings: Balancing Growth Potential and Uncertainty with a Hold Rating - TipRanks
Stifel Nicolaus Lowers ALX Oncology (NASDAQ:ALXO) Price Target to $1.50 - Defense World
ALX Oncology (NASDAQ:ALXO) Earns “Buy” Rating from HC Wainwright - Defense World
Why the Global Cancer Market Could Surpass $900 Billion-And the Stocks Leading the Charge - The Malaysian Reserve
Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge - PR Newswire
Sun Valley buying at Canagold Resources (CCM) - The Globe and Mail
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Jefferies Financial Group Upgrades ALX Oncology (NASDAQ:ALXO) to “Buy” - Defense World
Stifel cuts ALX Oncology stock target to $1.50, maintains hold By Investing.com - Investing.com Canada
Promising Developments in ALX Oncology’s Clinical Pipeline Justify Buy Rating - TipRanks
Jefferies raises ALX Oncology stock to buy, target to $3 By Investing.com - Investing.com South Africa
ALX Oncology Reports 2024 Financial Results and Updates - TipRanks
Micro-, Small-Cap Firms Dominate Market Rally - Insider Monkey
Alx Oncology Holdings Inc Files For Mixed Shelf Of Up To $364.1 Million -March 06, 2025 at 05:35 pm EST - Marketscreener.com
ALX Oncology Holdings Inc (ALXO) Q4 2024 Earnings: EPS of -$0.55 Beats Estimate, Revenue Matches Forecast - GuruFocus.com
ALX Oncology Holdings Inc reports results for the quarter ended December 31Earnings Summary - TradingView
ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - The Manila Times
ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results - TradingView
Can ALX Oncology's 49% Cancer Trial Success Transform Gastric Cancer Treatment? - StockTitan
ALX Oncology jumps as Jefferies upgrades on upside potential - MSN
ALX Oncology stock jumps as Jefferies upgrades(ALXO:NASDAQ) - Seeking Alpha
This Zscaler Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday - Benzinga India
ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 - Barchart
ALX Oncology Cuts 30% Workforce, Eliminates President And CSO Role Amid Pipeline Prioritization - Nasdaq
Jefferies Upgrades ALX Oncology to Buy From Hold, Adjusts Price Target to $3 From $2 - Marketscreener.com
Jefferies Upgrades ALX Oncology Holdings (ALXO) - Nasdaq
ALX Oncology Holdings: Undervalued with Promising Catalysts and Growth Opportunities - TipRanks
Jefferies raises ALX Oncology stock to buy, target to $3 - Investing.com
ALX Oncology announces workforce reduction and officer departure By Investing.com - Investing.com Australia
ALX Oncology announces workforce reduction and officer departure - Investing.com India
ALX Oncology Announces Workforce Reduction and Leadership Change - TipRanks
ALX Oncology to Cut Workforce by 30% to Support New Clinical Initiatives -March 05, 2025 at 11:04 am EST - Marketscreener.com
ALX Oncology Highlights Focused Evorpacept Development - GlobeNewswire
ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event - Yahoo Finance
ALXO stock plunges to 52-week low, touches $0.96 By Investing.com - Investing.com Australia
ALXO stock plunges to 52-week low, touches $0.96 - Investing.com
ALX Oncology (ALXO) to Release Earnings on Thursday - MarketBeat
When Will ALX Oncology Share Its 2024 Financial Performance? Key Date for Biotech Investors - StockTitan
ALX Oncology (ALXO) Projected to Post Earnings on Thursday - Defense World
H.C. Wainwright cuts ALX Oncology target to $5, keeps buy rating - MSN
Alx oncology SVP Shelly Pinto sells $632 in common stock By Investing.com - Investing.com Australia
Alx oncology ceo Jason Lettmann sells shares for $2,483 By Investing.com - Investing.com Australia
Alx oncology president Jaume Pons sells $1,525 in stock By Investing.com - Investing.com Nigeria
Alx oncology SVP Shelly Pinto sells $632 in common stock - Investing.com India
Alx oncology president Jaume Pons sells $1,525 in stock - Investing.com India
Alx Oncology Holdings Inc Stock (ALXO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):